2020 IPO

ORIC Pharmaceuticals Stock

Biopharmaceutical company

Sign up today and learn more about ORIC Pharmaceuticals Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

Memorial Sloan - Kettering Cancer Center


South San Francisco CA, US

Total Funding


About ORIC Pharmaceuticals Stock

ORIC Pharmaceuticals is a privately-held company dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to current drugs. Relapsed patients lack further treatment options. ORIC has assembled a world-class scientific team dedicated to the discovery of therapies that can meaningfully improve clinical outcomes for these patients.


Funding History

November 2014$15.4M
November 2015$54.0M
February 2018$53.4M
August 2019$55.0M


Chief Executive Officer

Jacob Chacko

Chief Scientific Officer

Lori Friedman

Chief Medical Officer

Pratik Multani

Chief Business Officer

Matthew Panuwat

Chief Financial Officer

Dominic Piscitelli


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: